Unpacking Phase 3 Data from TETON 1 & TETON 2: Evaluating Nebulized Treprostinil as a Potential Disease-Modifying Therapy for IPF

• Presenting results from the Phase 3 TETON clinical program investigating nebulized treprostinil in idiopathic pulmonary fibrosis, including its impact on decline in forced vital capacity and overall disease progression
• Examining the biological and clinical rationale for targeting the prostacyclin pathway in fibrotic lung disease, building on signals observed in patients with IPF in the INCREASE study
• Discussing the implications of the TETON findings for the future treatment paradigm in IPF, including the role inhaled therapies may play alongside existing antifibrotics and in combination strategies

Speakers:

Franck Rahaghi

Executive Director - Cardiopulmonary & Global Medical Affairs

United Therapeutics Corp.